Pam Medical, a medical device company, has completed a $100 million Series D financing round led by Medtronic, a global medical device giant.

Pulnovo Medical, a pioneer in breakthrough therapies for pulmonary hypertension and heart failure, recently announced the successful completion of an oversubscribed $100 million financing round. This financing round was led by global medical device giant Medtronic. Existing investors such as EQT, Qiming Venture Partners, Banyan Capital, OrbiMed, and Lilly Asia Ventures continued to participate, and multiple well - known global institutional investors including Sequoia China also joined this round. This financing round is an important milestone in Pulnovo Medical's global development process, fully demonstrating the high recognition of the company's technological strength, clinical progress, and long - term vision by leading strategic and institutional investors.

Meanwhile, Medtronic and Pulnovo Medical have signed a commercial cooperation agreement, laying the framework foundation for potential future commercial cooperation between the two parties. This agreement aims to fully leverage the commercial synergy between Pulnovo Medical and Medtronic and jointly promote the wide application of innovative therapies with the help of Medtronic's unique and profound global commercialization capabilities.

Pulnovo Medical's independently developed Pulmonary Artery Denervation (PADN) system precisely targets the core pathogenesis of cardiopulmonary diseases and has shown significant clinical benefits in terms of improving functional capacity and patient prognosis. Currently, the company has completed approximately 1,500 PADN surgeries globally and has obtained regulatory approvals in seven countries, continuously deepening its international market layout. At present, Pulnovo Medical is actively promoting the commercialization process in the European Union, the Middle East, and China markets.

In the US market, Pulnovo Medical has obtained FDA Breakthrough Device Designation and has launched two fully approved Investigational Device Exemption (IDE) clinical trials, both of which are led by Professor Gregg Stone from the Icahn School of Medicine at Mount Sinai.

"By integrating industrial resources and long - term capital, Pulnovo Medical is building a sustainable growth model centered on independent innovation, with global clinical development as the path and strategic ecosystem cooperation as the support. This financing round marks the company's key transformation from the product - driven stage to a global integrated platform. We will continue to strengthen our dual - wheel drive capabilities in clinical and technology and are committed to bringing valuable innovative therapies to global patients."

—Cynthia Chen, Chairman and President of Pulnovo Medical

Global - scale strategic cooperation layout

This financing round further deepens the strategic synergy between Pulnovo Medical and its global industrial and capital partners, comprehensively enhancing the company's comprehensive capabilities in promoting clinical R & D, global strategic deployment, and expanding commercial operations.

The funds raised in this financing round will be used to support continuous clinical R & D, global regulatory filings, international commercialization promotion, and continuous investment in the core technology platform.

Lian Jia, Executive Director and CEO of Pulnovo Medical said that the company is fully promoting the strategic transformation from clinical innovation - driven to a global operation system, accelerating the construction of a global integrated capability system covering R & D, clinical, and industrialization.

To support this strategic goal, Pulnovo Medical is continuously expanding its global leadership team. Andre Xiao has officially joined as the Chief Strategy Officer, leading global financing and strategic planning. He will closely collaborate with the board of directors to continuously deepen the company's connection with the global capital market and industrial ecosystem, helping the company move towards the next stage of growth. Andre has rich experience in healthcare investment and the global capital market and has worked in well - known investment institutions such as Citadel and Millennium Management, focusing on global medical device investment.

About Pulmonary Artery Denervation (PADN)

Pulnovo Medical's independently developed Pulmonary Artery Denervation (PADN) system is a globally innovative minimally invasive interventional therapy product that targets and intervenes in the core mechanisms of pulmonary vascular remodeling and the progression of cardiopulmonary diseases by regulating over - activated sympathetic nerve activity. Multiple global studies have confirmed that PADN shows clinically significant benefits in improving functional capacity and reducing major adverse clinical events.

This therapy has been included in multiple international clinical guidelines, including the 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension, and has been cited in seven clinical guidelines at home and abroad to date.

Multiple clinical studies are being simultaneously promoted in multiple regions around the world, and the recently launched PULSE - LHD IDE clinical trial in the United States will further consolidate the clinical evidence base of PADN and support its great potential in meeting the major unmet medical needs of patients with heart failure and related cardiopulmonary diseases.